Citations 1
P962: CHANGE IN SOLUBLE BCMA LEVEL MAY BE A SURROGATE MARKER OF EARLY RESPONSE TO THERAPY IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): PRELIMINARY RESULTS FROM A PHASE I STUDY OF CEVOSTAMAB
Nakamura, R., Hendricks, R., Dokhaei, Romina, Susilo, Monica Damayani, Wilson, D., Trudel, S., Cohen, Aaron B. , Harrison, S. J. , Krishnan, A., Adamkewicz, J. I., Li, M., Wong, C., Cooper, J., Sumiyoshi, T., Krishnan, A., Fonseca, Rodrigo
HemaSphere | June 30, 2022 | Volume: 6 | Issue: No issue available | Pages: 852-853
